Inhibrx Biosciences Inc (INBX)
14.90
-0.55
(-3.56%)
USD |
NASDAQ |
Nov 14, 13:11
Inhibrx Biosciences Enterprise Value: -3.207M for Nov. 13, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2024 | -3.207M |
| November 12, 2024 | 13.15M |
| November 11, 2024 | 4.754M |
| November 08, 2024 | 7.794M |
| November 07, 2024 | 8.518M |
| November 06, 2024 | 5.478M |
| November 05, 2024 | 0.5564M |
| November 04, 2024 | -1.760M |
| November 01, 2024 | 1.859M |
| October 31, 2024 | 5.189M |
| October 30, 2024 | 8.952M |
| October 29, 2024 | 6.202M |
| October 28, 2024 | 4.754M |
| October 25, 2024 | -4.365M |
| October 24, 2024 | -4.365M |
| October 23, 2024 | 1.280M |
| October 22, 2024 | 1.859M |
| October 21, 2024 | -2.484M |
| October 18, 2024 | 4.754M |
| October 17, 2024 | 7.215M |
| October 16, 2024 | 5.478M |
| October 15, 2024 | 0.9907M |
| October 14, 2024 | -2.484M |
| October 11, 2024 | -0.4569M |
| October 10, 2024 | -1.326M |
| Date | Value |
|---|---|
| October 09, 2024 | -0.0226M |
| October 08, 2024 | 4.610M |
| October 07, 2024 | -5.813M |
| October 04, 2024 | -13.20M |
| October 03, 2024 | -11.46M |
| October 02, 2024 | -3.931M |
| October 01, 2024 | -3.207M |
| September 30, 2024 | -0.1674M |
| September 27, 2024 | -2.194M |
| September 26, 2024 | -4.944M |
| September 25, 2024 | -3.642M |
| September 24, 2024 | -2.484M |
| September 23, 2024 | -0.0226M |
| September 20, 2024 | 8.808M |
| September 19, 2024 | 26.32M |
| September 18, 2024 | 19.09M |
| September 17, 2024 | 22.42M |
| September 16, 2024 | 25.45M |
| September 13, 2024 | 10.69M |
| September 12, 2024 | -8.563M |
| September 11, 2024 | -9.722M |
| September 10, 2024 | -7.116M |
| September 09, 2024 | -6.826M |
| September 06, 2024 | -8.853M |
| September 05, 2024 | 5.333M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-67.05M
Minimum
Aug 09 2024
260.86M
Maximum
Jun 03 2024
29.47M
Average
-3.207M
Median
Oct 01 2024
Enterprise Value Benchmarks
| CEL-SCI Corp | 38.36M |
| AIM ImmunoTech Inc | 7.900M |
| IGC Pharma Inc | 26.09M |
| NovaBay Pharmaceuticals Inc | 3.432M |
| Protalix BioTherapeutics Inc | 66.58M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 1.858B |
| Revenue (Quarterly) | 0.10M |
| Total Expenses (Quarterly) | 161.00M |
| EPS Diluted (Quarterly) | 125.48 |
| Earnings Yield | 778.1% |